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Abstract
The HIV-1 accessory factor Nef is essential for high-titer viral replication and AIDS progression. Nef function requires
interaction with many host cell proteins, including specific members of the Src kinase family. Here we explored whether Src-
family kinase activation is a conserved property of Nef alleles from a wide range of primary HIV-1 isolates and their
sensitivity to selective pharmacological inhibitors. Representative Nef proteins from the major HIV-1 subtypes A1, A2, B, C,
F1, F2, G, H, J and K strongly activated Hck and Lyn as well as c-Src to a lesser extent, demonstrating for the first time that
Src-family kinase activation is a highly conserved property of primary M-group HIV-1 Nef isolates. Recently, we identified 4-
amino substituted diphenylfuropyrimidines (DFPs) that selectively inhibit Nef-dependent activation of Src-family kinases as
well as HIV replication. To determine whether DFP compounds exhibit broad-spectrum Nef-dependent antiretroviral activity
against HIV-1, we first constructed chimeric forms of the HIV-1 strain NL4-3 expressing each of the primary Nef alleles. The
infectivity and replication of these Nef chimeras was indistinguishable from that of wild-type virus in two distinct cell lines
(U87MG astroglial cells and CEM-T4 lymphoblasts). Importantly, the 4-aminopropanol and 4-aminobutanol derivatives of
DFP potently inhibited the replication of all chimeric forms of HIV-1 in both U87MG and CEM-T4 cells in a Nef-dependent
manner. The antiretroviral effects of these compounds correlated with inhibition of Nef-dependent activation of
endogenous Src-family kinases in the HIV-infected cells. Our results demonstrate that the activation of Hck, Lyn and c-Src by
Nef is highly conserved among all major clades of HIV-1 and that selective targeting of this pathway uniformly inhibits HIV-1
replication.
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Introduction
The HIV-1 nef gene encodes a small myristoylated protein
expressed early in the HIV-1 life cycle [1–3]. Nef, one of several
accessory factors unique to primate lentiviruses, is not required for
HIV-1 replication in vitro [4] but is essential for high-titer virus
replication [5–9] and AIDS pathogenesis in vivo [10–13]. Nef has
no known enzymatic activity, and appears to exert its effects by
interacting with a diverse group of host cell proteins involved in
cellular activation, immune recognition and survival [14,15].
Many protein-protein interaction motifs have been mapped to the
Nef structure, which account for its diverse functions including
down-regulation of CD4 and MHC-1 molecules and activation of
cellular signaling pathways [9,16–37]. The essential role for Nef in
HIV pathogenesis is highlighted by the requirement for this
accessory factor in SIV-induced AIDS in non-human primates,
and the observation that Nef-defective forms of HIV-1 have been
detected in some long-term non-progressors who are seropositive
but fail to develop AIDS [10,38]. Furthermore, the CD4
promoter-directed expression of Nef alone to HIV target cells in
transgenic mice is sufficient for the development of an AIDS-like
syndrome characterized by CD4+ T cell depletion, diarrhea,
wasting, and 100% mortality [39], supporting a major role for Nef
in HIV-1 pathogenicity.
One important group of Nef-interacting proteins includes
members of the Src protein-tyrosine kinase family [40]. Nef
directly binds and activates a subset of Src-family kinases (SFKs),
namely Hck, Lyn and c-Src [41–44]. Of these, Hck is strongly
expressed in macrophages and dendritic cells, while c-Src and Lyn
exhibit broader expression patterns including all HIV target cell
types. Suppression of Hck expression with antisense oligonucleo-
tides dramatically inhibits macrophage-tropic HIV-1 replication in
primary human macrophages [45]. In brain-derived microglial
cells, HIV-1 infection induces Nef-dependent Hck activation;
suppression of Nef-Hck activity via expression of dominant-
negative Hck or CD45 phosphatase inhibits HIV replication [46].
In addition, Nef-induced AIDS-like disease is delayed in Hck-null
mice and completely reversed in mice expressing a Nef mutant
unable to bind to Hck [39,47]. Taken together, these results
underscore the importance of Nef-SFK interaction in HIV
replication and AIDS pathogenesis.
Nef interacts with SFKs by binding to their SH3 domains.
Structural studies of the Nef-SH3 interface reveal that the
interaction involves a highly conserved PxxPxR motif on Nef as
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well as a hydrophobic pocket formed by the three-dimensional fold
of the Nef core region [48,49]. Subsequent studies revealed that
Nef binding induces constitutive activation of Hck and other SFKs
by displacing the SH3 domain from its negative regulatory
interaction with the SH2-kinase linker on the back of the kinase
domain [41–43]. Activation requires both the Nef PxxPxR motif
and hydrophobic pocket, and may induce a unique activated
conformation of the partner kinase [43,50,51]. In addition to these
highly conserved Nef regions directly involved in SH3 engage-
ment, studies of Nef alleles derived from long-term non-
progressors have shown that residues at a distance from the SH3
binding site also impact Nef-dependent Hck activation, possibly
through an allosteric mechanism [52]. Thus sequence alignments
alone do not necessarily predict the ability of primary Nef
sequences to induce kinase activation.
In the first part of this study, we evaluated whether SFK SH3
domain binding and kinase activation are indeed properties
common to Nef alleles representative of all major HIV-1 subtypes.
We found that primary Nef proteins derived from the major clades
of HIV-1 bind to the Hck SH3 domain and activate recombinant,
downregulated Hck in vitro. All of the primary Nef proteins also
activated Hck and Lyn (and c-Src to lesser extent) in cells, while
producing no detectable effect on other SFKs. These results
establish that SFK activation is indeed a function shared by Nef
alleles derived from all major HIV-1 subtypes.
The highly conserved nature of Nef-SFK activation and its
importance to HIV-1 replication and pathogenesis has raised
interest in this signaling pathway as a therapeutic target. Recently,
our laboratory developed a high-throughput screening assay for
inhibitors of Nef-mediated Hck activation in vitro. This effort led to
the discovery of 4-amino-substituted diphenylfuropyrimidine
(DFP) compounds with low micromolar activity against both
Nef-mediated Hck activation and Nef-dependent HIV-1 replica-
tion in cell culture [53]. These prior studies were conducted with
two laboratory strains of HIV-1, SF2 and NL4-3, raising the
question of the broader applicability of these compounds against
the many allelic variants of HIV-1 Nef. Therefore, we investigated
the effect of the DFP analogs on both primary Nef-mediated Hck
activation as well as replication of HIV-1 NL4-3 Nef chimeras that
express each primary Nef protein. Active analogs of DFP identified
in our previous work potently inhibited primary Nef-mediated
Hck activation in vitro as well as replication of all of the HIV-1 Nef
chimeras. These results validate the Nef-SFK signaling axis as a
viable target for development of broad-based inhibitors as a new
approach to anti-retroviral therapeutics.
Results and Discussion
One of the major objectives of this study was to address whether
SH3 domain-mediated activation of SFKs is conserved across
primary Nef alleles derived from all M-group clades of HIV-1. To
address this question, we assembled a set of Nef cDNA clones
representative of all major non-recombinant HIV-1 subtypes. We
first queried the NIH HIV-1 sequence database [54] to obtain
sequences of Nef alleles from patient isolates of HIV-1 clades A1,
A2, B, C, D, F1, F2, G, H, J and K. These clades are
representative of the major subgroup of HIV-1 strains responsible
for more than 90% of HIV-1 infections associated with the global
HIV/AIDS pandemic [55–57]. Each of these sequences was
translated in silico and those that encoded truncated Nef proteins
were eliminated. Of the remaining sequences, one from each clade
was aligned together with the laboratory alleles Nef-SF2 (clade B)
and Nef-ELI (clade D). These two Nef variants have been studied
extensively by our group in terms of Nef-mediated SFK activation,
and serve as useful controls [43,44,50]. The alignment revealed
strong conservation of known residues and motifs essential for SFK
SH3 domain binding and kinase activation, including the PxxPxR
motif and the hydrophobic pocket residues F90, W113, and Y/
F120 (Figure 1). A model of the contributions of each of these
residues to the Nef:SH3 interface, based on the crystal structure of
Lee et al. [48], is shown in Figure 2. Note that while substitution of
Y120 with isoleucine in Nef-ELI (clade D) prevents it from binding
and activating Hck in vitro and in vivo [50], alignments of a larger
group of primary Nef D-clade alleles revealed that this substitution
is quite rare (data not shown). In addition to the SH3 domain
binding site, there is also strong conservation of residues that form
the Nef dimerization interface (K/R105, L112, Y115, F121, and
D123). Dimerization is critical to many Nef functions, including
support of HIV-1 replication and SFK activation, and mutations
of the residues that make up the dimer interface in the crystal
structure interfere with these Nef functions as well as Nef
dimerization in a cell-based fluorescence complementation assay
[58–60]. Figure 2 also shows a model of Nef:SH3 dimers, as well
as close-up views of the Nef:SH3 and Nef:Nef interfaces.
To evaluate the functional properties of our M-group HIV-1
Nef clade set, we first expressed the recombinant Nef proteins in E.
coli and purified them to homogeneity. As shown in Figure 3A,
most of these primary Nef sequences yielded soluble recombinant
proteins, with the exceptions of Nef-C and Nef-H. All of the
recombinant Nef proteins eluted as single symmetrical peaks by gel
filtration, and their molecular weights were confirmed by mass
spectrometry (data not shown).
We first evaluated the binding of purified Nef proteins to the
Hck SH3 domain. Because SH3 interaction requires the proper
three-dimensional fold of the Nef core [48,49], these studies
provided an assessment of whether our recombinant purified Nef
proteins folded correctly in bacteria. The wild-type Hck SH3
domain, as well as a binding-defective mutant (W93A; [61]), were
expressed in bacteria as GST fusion proteins and purified using
glutathione-agarose beads. Wild-type GST-SH3, the GST-SH3-
W93A mutant control, as well as GST alone were incubated with
purified recombinant Nef proteins, followed by extensive washing.
Bound Nef was then visualized by immunoblot analysis. As shown
in Figure 3B, all primary Nef proteins showed robust binding to
the wild-type Hck SH3 domain, while no binding was observed
with the W93A mutant or with GST alone. As an additional
control, we also prepared recombinant Nef-ELI, the rare D-clade
allele that lacks the hydrophobic pocket residue Y120 and thus
fails to activate Hck [44]. As expected, Nef-ELI failed to bind to
the Hck SH3 domain in this assay. Taken together, these data
show that Hck SH3 domain binding is a conserved property of Nef
proteins derived from M-group HIV-1 isolates.
Previous studies have established that Nef activates Hck (and
other Src-family members) through displacement of the SH3
domain from its regulatory interaction with the SH2-kinase linker
[42,44]. Thus, Nef must have sufficient binding affinity to compete
for the internal SH3-linker interactions present in the downreg-
ulated forms of Src-family kinases [40]. To determine whether the
SH3-binding activity of our primary Nef proteins was sufficient to
induce Hck activation, we turned to the FRET-based Z9-Lyte
kinase assay which we have used previously to demonstrate Nef-
mediated Hck activation in vitro (see Materials and Methods).
Purified, downregulated Hck was incubated in the absence or
presence of a 10-fold molar excess of each Nef protein prior to
assay. As shown in Figure 3C, all of the primary Nef proteins
activated Hck in the Z9-Lyte assay, demonstrating for the first time
that Hck activation is a highly conserved property of M-group Nef
alleles, despite considerable sequence variation.
Broad-Based Inhibitors of HIV-1 Nef Signaling
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Studies with recombinant Nef proteins derived from primary
HIV-1 sequences all exhibited SH3-binding and Hck activation
(Figure 3). However, we were not able to assess the activity of
Nef-C and Nef-H, because soluble recombinant proteins could
not be obtained from these sequences. To assess the interaction of
these Nef proteins with Hck, and to expand our study to other
members of the Src kinase family in a cell-based assay, we turned
to a yeast system previously used by our group [44,52]. In this
assay, Hck and other Src-family kinases are expressed with
modified ‘‘YEEI’’ tails so that they adopt the downregulated
conformation in the absence of the negative regulatory kinase,
Csk. This point is important because active Src-family kinases
cause growth arrest in yeast [44]. To assess primary Nef-induced
SFK activation in this system, yeast cultures were co-transformed
with expression plasmids for each primary Nef sequence and Src
family member, and colonies were selected on glucose agar to
repress protein expression from the Gal promoter. Transformed
colonies were then grown in liquid medium with galactose as sole
carbon source to induce Nef and SFK expression. The cultures
were lysed, and SFK activation was evaluated by immunoblotting
with anti-phosphotyrosine antibodies. Nef-SF2 and Nef-ELI
served as positive and negative controls, respectively. As shown
in Figure 4, Nef-SF2 strongly activated Hck while Nef-ELI failed
to do so, consistent with our previous data [44]. All of the
primary Nef alleles tested also induced dramatic Hck activation,
as reflected by the strong phosphorylation of yeast cell proteins in
comparison to downregulated Hck-YEEI alone. Control exper-
iments show that the Nef proteins do not affect yeast cell growth
or protein-tyrosine phosphorylation when expressed in the
absence of Hck-YEEI (Figure S1 and data not shown). Similar
results were obtained with Lyn, although tyrosine phosphoryla-
tion of yeast cell proteins was less extensive for this Src-family
member and may reflect more stringent substrate protein
selection relative to Hck. Interestingly, Lyn also appeared to
strongly phosphorylate most Nef isoforms, including A2, B, C,
F2, G, H, and K, as well as SF2 (Figure 5). Variation in the extent
of Nef phosphorylation by Lyn may reflect the variability in the
number and position of the tyrosine residues present in individual
Nef proteins. SFK-dependent tyrosine phosphorylation of Nef in
HIV host cells may influence its function or interaction with other
binding partners.
In addition to Hck and Lyn, we also evaluated the effect of the
primary Nef alleles on other SFKs expressed in HIV-1 target cells.
All of the Nef alleles induced partial activation of c-Src in this
system (Figure S2), which was more apparent in growth
suppression assays than the anti-phosphotyrosine immunoblots
with the exceptions of Nef-F2 and Nef-H (Figure S3). In contrast,
no activation of Lck, Fyn or Fgr was observed with any of the
primary Nef alleles tested (Figure S4). These data demonstrate that
Hck and Lyn (and c-Src to a lesser extent) are selectively activated
by M-group HIV-1 Nef proteins, supporting a role for these
kinases as direct Nef effectors in HIV-infected cells.
Figure 1. Sequence alignment of primary and laboratory Nef alleles used in this study. Nef cDNA clones representative of all major non-
recombinant HIV-1 clades were selected from the NIH HIV-1 sequence database as described in the text. The first letter in each clone ID (bold)
indicates the subtype assignment. This Clustal W alignment also includes Nef-SF2 (top), which has been studied extensively in our laboratory in terms
of Hck activation [41,43,44,50,53], as well as Nef-ELI, which fails to activate Hck or other SFKs [44,50]. Key residues in the SF2 sequence that are
essential for SH3 binding are shown in red, and include the PxxPxR motif and hydrophobic pocket residues F90, W113, and Y/F120. In Nef-ELI, Y120 is
replaced with isoleucine (highlighted in yellow); this single substitution accounts for loss of SH3 engagement and Hck activation [50]. Residues
involved in Nef dimerization include K/R105, L112, Y115, F121, and D123 (blue). Flanking N- and C-terminal Nef sequences are more variable and have
been omitted for clarity.
doi:10.1371/journal.pone.0032561.g001
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Recently we described a screening assay for small molecule
inhibitors of Nef-dependent Hck activation in vitro [53]. Using
this assay, we identified a series of 4-amino-diphenylfuropyr-
imidines (DFPs) as potent inhibitors of both Nef-SF2-mediated
Hck activation and Nef-dependent HIV-1 replication. Because
these compounds represent potential leads for Nef-directed HIV-
1/AIDS therapeutics, we next examined whether these com-
pounds inhibit Hck following activation by each of the
recombinant primary Nef proteins using the Z9-Lyte kinase
assay. As shown in Figure 6, both the 4-aminopropanol and 4-
aminobutanol derivatives of DFP inhibited primary Nef-induced
Hck activation by more than 50% at 10 mM. Remarkably, the
inhibitory action of both compounds was more pronounced with
the primary Nef proteins than with Nef-SF2, the laboratory
allele originally used to develop the screen. In contrast, the
unsubstituted 4-amino DFP pharmacophore was without effect,
consistent with our previous results [53]. These data demonstrate
that 4-amino substituted derivatives of DFP are broadly active
against the Hck:Nef complex independent of the Nef isolate
used.
Figure 2. Structural features of the Nef:SH3 and Nef dimerization interfaces. A) Overview of the Nef:SH3 dimer X-ray crystal structure,
based on the crystal coordinates of Lee, et al. (PDB: 1EFN) [48]. The monomeric Nef core subunits are modeled in blue and green respectively; the SH3
domains are shown in red. B) Close-up view of the Nef:SH3 interface. Nef residues P72 and P75 define a polyproline type II helix that meshes with the
hydrophobic grooves of the SH3 surface, and is oriented and stabilized by an ionic interaction between Nef R77 and SH3 D100. High affinity
interaction also requires a hydrophobic pocket formed in part by Nef residues F90, W113, and Y120. This pocket engages SH3 domain RT loop I96
(Van der Waals surface shown as dots). Mutagenesis of either Nef Y120 or SH3 I96 is sufficient to disrupt Nef:SH3 interaction [50,66]. C) Close-up view
of the Nef dimerization interface. Dimer packing involves hydrophobic interactions of side chains of the aB helices (L112, Y115, F121) which are
orthogonally opposed. This hydrophobic core is capped on both ends by ionic interactions involving D123 and R105.
doi:10.1371/journal.pone.0032561.g002
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Previous work from our group and others has established that
Nef expression is essential for optimal replication of HIV-1 in the
astroglioma cell line U87MG which has been engineered to
express CD4 and the co-receptor CXCR4, and in the T-cell line,
CEM-T4 [53,62,63]. Replication of HIV-1 strain NL4-3 is
potently inhibited by 4-amino-substituted DFP compounds in
the U87MG model system, and this inhibitory effect is dependent
upon the expression of Nef [53]. In order to investigate the
broader utility of the DFP compounds against M-group HIV-1
isolates, we first needed to demonstrate functional enhancement of
HIV-1 replication by each of our primary Nef alleles in these cell
lines. To accomplish this goal, we generated a series of HIV-1
NL4-3 chimeras in which the NL4-3 Nef sequence was replaced
by each of the representative M-group Nef coding sequences. The
resulting chimeric viruses were first used to infect the T cell line
MT-2, where they induced syncitia formation indistinguishable
from wild-type NL4-3 and replicated strongly (data not shown).
We then evaluated the ability of each primary Nef allele to
Figure 3. Purified primary Nef proteins bind to the Hck SH3 domain and activate downregulated Hck in vitro. A) SDS-PAGE of
recombinant purified proteins. Each of the indicated Nef subtypes were expressed in bacteria and purified with N-terminal His-tags (left). GST and GST
fusion proteins with the Hck SH3 domain (wild-type and W93A mutant) were also expressed in bacteria and immobilized on glutathione-agarose
beads (right). Protein aliquots were resolved by SDS-PAGE and stained with Coomassie blue. B) Nef-SH3 binding assay. Recombinant His-tagged Nef
proteins (1 mg) were incubated with equimolar amounts of immobilized GST and GST-SH3 fusion proteins. The agarose beads were then washed, and
associated Nef proteins were detected by immunoblotting using antibodies to the His-tags. C) Nef-induced Hck activation. Kinase activity of
recombinant downregulated Hck (Hck-YEEI; [44,52,53] was determined in the absence or presence of the indicated Nef proteins using the Z-Lyte
assay as described under Materials and Methods. Results are expressed as the mean percent of maximum substrate phosphorylation 6 S.D.; this
experiment was repeated twice with comparable results.
doi:10.1371/journal.pone.0032561.g003
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enhance HIV-1 replication in U87MG-CD4+/CXCR4+ cells. As
observed previously, Nef-defective HIV-1 replicated very poorly in
this cell line (Figure 7A). However, replication of each of the Nef
chimeras was indistinguishable from wild-type HIV-1 NL4-3,
demonstrating that these Nef proteins function to support HIV
replication. Immunoblots (Figure 7B) demonstrate that each Nef
variant is expressed in infected cells, along with major capsid
proteins. Similarly, replication of Nef-defective HIV-1 replicated
to only 10% of wild-type levels in CEM-T4 cells, and this
replication defect was completely rescued by cis-complementation
with all of the primary Nef alleles tested (Figure 8A). Immuno-
blotting verified Nef expression in CEM-T4 cells infected with
wild-type HIV-1 and each of the chimeras, as well as capsid
proteins (Figure 8B). These results demonstrate that HIV-1
replication is Nef-dependent in both the U87MG-CD4+/
CXCR4+ and CEM T4 cell lines, providing an important new
tool to assess the broad efficacy of small molecule inhibitors of Nef
function on M-group HIV-1 replication.
As described in the preceding sections, 4-amino substituted DFP
analogs are potent inhibitors of both Nef-dependent SFK
activation and HIV replication [53]. Two DFP derivatives,
DFP-4-AP and DFP-4-AB, inhibited Hck activation by all of the
recombinant M-group Nef proteins tested (Figure 6), suggesting
that they may inhibit replication of the HIV-1 chimeras expressing
each of these primary Nef alleles as well. To test this possibility, we
infected both U87MG-CD4+/CXCR4+ and CEM-T4 cells with
wild-type HIV-1 NL4-3, the Nef-defective mutant and the Nef
chimeras in the absence or presence of DFP-4-AP or DFP-4-AB.
As shown in Figure 9, both of these DFP analogs inhibited
replication of wild-type HIV-1, as well as all of the Nef chimeras,
by more than 75% at a concentration of 3 mM in both cell lines. In
contrast, the compounds had no impact on the replication of Nef-
defective HIV-1, demonstrating that the antiretroviral activity of
the DFP analogs requires the expression of Nef. As with the in vitro
kinase assays, the unsubstituted 4-amino DFP pharmacophore was
completely inactive, consistent with our original observations [53].
In a final series of experiments, we investigated the effect of
HIV-1 infection on endogenous SFK activation in CEM-T4 T
cells, as well as the impact of the DFP-based inhibitors on HIV-
mediated kinase activation. For these studies, CEM-T4 cells were
infected with wild-type HIV NL4-3, the Nef-defective mutant, as
well as each of the eleven Nef chimeras. Infected cells were lysed
and SFK activity was monitored with a phosphospecific antibody
that recognizes the phosphotyrosine residue in the activation loop
of active SFKs (pY418). As shown in Figure 10, HIV infection
resulted in a Nef-dependent increase in endogenous Src-family
kinase activation in every case. Immunoblots with SFK isoform-
specific antibodies revealed that CEM-T4 cells express the direct
Nef targets c-Src and Hck (Figure S5), which are likely to be the
SFKs activated by HIV infection in this system. Furthermore,
when cells were treated with DFP-4AB or DFP-4AP, both of
which block Nef-dependent HIV-1 replication (Figure 9), SFK
activation was inhibited. In contrast, the inactive DFP analog,
DFP-4A, had no effect on kinase activity. These data provide
important new evidence that HIV-1 infection results in sustained
SFK activation in a Nef-dependent manner. This function is
Figure 4. Primary M-group HIV-1 Nef proteins strongly activate
Hck in cells. Yeast cultures were transformed with a galactose-
inducible expression plasmid for Hck-YEEI, which carries a modified C-
terminal tail that enables downregulation in the absence of Csk [52], or
the empty expression plasmid as a negative control (Con). Where
indicated, Hck-YEEI cells were co-transformed with galactose-inducible
vectors for Nef-ELI, Nef-SF2, and ten primary Nef alleles (A1, A2, B, C, F1,
F2, G, H, J, and K). Transformed cells were grown in liquid culture in the
presence of galactose at 30uC for 18 h. Protein extracts were separated
via SDS-PAGE and immunoblotted for tyrosine-phosphorylated proteins
(pTyr) as well as for Nef, Hck and actin as a loading control. Nef-ELI is
unable to interact with Hck and serves as an additional negative control
[52]. This experiment was repeated three times with comparable results.
doi:10.1371/journal.pone.0032561.g004
Figure 5. Primary M-group HIV-1 Nef proteins strongly activate
Lyn in cells. Yeast cultures were transformed with a galactose-
inducible expression plasmid for Lyn-YEEI, which carries a modified C-
terminal tail that enables downregulation in the absence of Csk [52], or
the empty expression plasmid as a negative control (Con). Where
indicated, Lyn-YEEI cells were co-transformed with galactose-inducible
vectors for Nef-ELI, Nef-SF2, and ten primary Nef alleles (A1, A2, B, C, F1,
F2, G, H, J, and K). Transformed cells were grown in liquid culture in the
presence of galactose at 30uC for 18 h. Protein extracts were separated
via SDS-PAGE and immunoblotted for tyrosine-phosphorylated proteins
(pTyr) as well as for Nef, Lyn and actin as a loading control. Nef-ELI is
unable to interact with Lyn and serves as an additional negative control
[52]. This experiment was repeated three times with comparable results.
doi:10.1371/journal.pone.0032561.g005
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shared by Nef alleles derived from all major HIV-1 clades in the
context of HIV-1 replication. Furthermore, this pathway is
sensitive to the DFP compounds, strongly supporting inhibition
of this pathway as their primary mechanism of action. These
results support the conclusion that therapeutic targeting of Nef-
dependent SFK activation may represent a broadly useful strategy
against HIV-1 replication.
In summary, our study demonstrates for the first time that Src-
family kinase binding and activation are highly conserved
properties of Nef isolates representative of all major HIV-1
subtypes. As observed previously for Nef proteins derived from
laboratory strains of HIV-1 such as SF2 [44,50], direct SFK
activation by Nef is limited to Hck and Lyn, with some activation
apparent for c-Src. These observations support the formation of
specific Nef-SFK complexes in all HIV target cell types. In
contrast, Fyn, Lck, and Fgr, which are also expressed in HIV host
cells, do not appear to be direct Nef effectors. In prior work, we
identified selective inhibitors of Nef-SF2-mediated Hck activation
in vitro that also blocked enhancement of HIV-1 replication by Nef
[53]. In the present study, we demonstrate that these 4-amino
substituted DFP analogs exhibit a broad spectrum of activity
against Nef:Hck complexes in vitro. Importantly, the DFP-based
compounds show equipotent inhibition of Nef-dependent HIV-1
replication against a panel of HIV-1 Nef chimeras representative
of all major HIV-1 clades. These observations strongly support the
development of 4-amino DFP analogs as a first step towards new
antiretroviral agents that target the interaction of this key HIV-1
virulence factor with host cell signaling proteins.
Materials and Methods
Expression vectors
Nucleotide sequences encoding representative Nef proteins from
the HIV-1 M-group subtypes A1, A2, B, C, F1, F2, G, H, J and K
were synthesized commercially (DNA2.0). The Nef sequences
were PCR-amplified and subcloned into the bacterial expression
vector pET14b (Novagen/EMD Biosciences). Construction of
similar bacterial expression vectors for Nef-SF2 and Nef-ELI has
been described [52]. For yeast studies, the Nef sequences from the
DNA2.0 plasmids were subcloned directly into the yeast
expression vectors pESC-Trp or pESC-Trp-Csk under the control
of the GAL10 promoter as described previously [44]. Similar
pESC and pYC2/CT-based vectors for yeast expression of Hck,
Lyn, Lck, Fyn, Fgr, and c-Src as well as the Herpesvirus saimiri Tip
protein have been reported previously by our group [44,52,64].
Cell lines and antibodies
Human 293T cells were obtained from the ATCC and grown in
Dulbecco’s Modified Eagle’s Medium/high glucose (Life Tech-
nologies) supplemented with 10% fetal bovine serum (Gemini Bio-
Products). U87MG-CD4+/CXCR4+, MT2 and CEM-T4 cells
were obtained from NIH AIDS Research and Reference Reagent
Program. U87MG-CD4+/CXCR4+ cells were grown in Dulbec-
co’s Modified Eagle’s Medium/high glucose supplemented with
25 mM HEPES, pH 7.4, 10% fetal bovine serum, G418 (400 mg/
ml) and puromycin (0.5 mg/ml); G418 and puromycin are
required to maintain expression of CD4 and CXCR4 in this cell
Figure 6. Diphenylfuropyrimidine (DFP) analogs are broadly active against primary Nef-mediated Hck activation. A) Structures of 4-
amino DFP (DFP-4A) and the corresponding 4-aminopropanol (DFP-4AP) and 4-aminobutanol (DFP-4AB) analogs. B) The activity of recombinant
downregulated Hck (Hck-YEEI) [44,52,53] was determined in the absence or presence of the indicated Nef proteins as described under Materials and
Methods. Reactions were run in the presence of 10 mM concentrations of DFP-4A, DFP-4AP, DFP-4AB, or the DMSO carrier solvent as negative control.
Results are expressed as the mean percent of maximum substrate phosphorylation 6 S.D.; this experiment was repeated twice with comparable
results.
doi:10.1371/journal.pone.0032561.g006
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line. MT2 and CEM-T4 cells were grown in RPMI 1640 medium
(Life Technologies) supplemented with 10% fetal bovine serum
and 2 mM L-glutamine.
Antibodies used in this study were obtained from the NIH AIDS
Research and Reference Reagent Program (Nef, 2949; p24, 4121),
Santa Cruz Biotechnology (pY99, sc-7020; Hck, sc-72; Lyn, sc-15;
Fyn, sc-16; Lck, sc-13; c-Src, sc-18; Csk, sc-286; Fgr, sc-17; pan-
specific SFK, sc-5266; His-tag, sc-803; GST, sc-138), Abcam (c-
Yes, Ab13954), Life Technologies (SFK pY418, 44660G) and
Millipore (actin, MAB 1501).
Nef and Hck protein purification
E. coli strains BL21 DE3 Rosetta2 (Novagen) or Arctic Express
(Stratagene) were transformed with pET14b-Nef plasmids and
protein expression was induced with 0.5 mM IPTG at 28uC for
4 h (Rosetta2) or 11uC for 24 h (Arctic Express). The bacterial
cells were collected by centrifugation and lysed in His-lysis buffer
(20 mM Tris-HCl, pH 8.3, 500 mM NaCl, 20 mM imidazole,
10% glycerol and 5 mM b-mercaptoethanol). Lysates were
clarified by centrifugation at 30,0006g at 4uC for 30 min. The
His-tagged Nef proteins were purified by Ni-NTA affinity
chromatography using an A¨KTAexplorer automated chromatog-
raphy system (GE Healthcare). Lysates containing His-tagged Nef
were loaded on a Ni-NTA HiTrap Chelating HP column (5 ml;
GE Healthcare) pre-equilibrated with lysis buffer. After washing
with 2 column volumes (CV) of lysis buffer, proteins were eluted in
His-elution buffer (20 mM Tris-HCl, pH 8.3, 1 M imidazole,
10% glycerol and 5 mM b-mercaptoethanol) with a linear
gradient of 20 mM to 1 M imidazole over 6 CV. The His-tagged
Nef proteins were further purified by gel filtration chromatography
on a HiLoad 26/60 Superdex 75 column (GE Healthcare) with
20 mM Tris-HCl, pH 8.3, 100 mM NaCl and 3 mM DTT as
Figure 7. Replication of HIV-1 Nef chimeras in U87MG-CD4+/
CXCR4+ cells. A) U87MG- CD4+/CXCR4+ cells (26104 per well of a 96-
well plate) were infected with 200 pg p24 equivalents/ml of wild-type
HIV-1 NL4-3, a Nef-defective mutant (DNef), or the indicated Nef
chimeras in a final culture volume of 200 ml. HIV p24 levels were
determined by ELISA 5 days later. Data are presented as percent of p24
release observed relative to the HIV-1 NL4-3 control 6 S.D. B) U87MG-
CD4+CXCR4+ cells (16105 per well of a 6-well plate) were infected with
1 ng p24 equivalents/ml of the same panel of viruses as in part A. Viral
Nef and gag protein expression was verified by immunoblotting lysates
of infected cells 4 days later. Lysates from uninfected cells are included
as a negative control (U87MG; far left lane).
doi:10.1371/journal.pone.0032561.g007
Figure 8. Replication of HIV-1 Nef chimeras in CEM-T4 cells. A)
CEM-T4 cells (16104 per well of a 96-well plate) were infected with
62.5 pg p24 equivalents/ml of wild-type HIV-1 NL4-3, a Nef-defective
mutant (DNef), or the indicated Nef chimeras in a final culture volume
of 200 ml. HIV p24 levels were determined by ELISA 10 days later. Data
are presented as percent of p24 release observed relative to the NL4-3
control 6 S.D. B) CEM-T4 cells (56105 per well of a 6-well plate) were
infected with 1 ng p24 equivalent/ml of the same panel of viruses as in
part A. Viral Nef and gag protein expression was verified by
immunoblotting lysates of infected cells 6 days later. Lysates from
uninfected cells are included as a negative control (CEM-T4; far left
lane).
doi:10.1371/journal.pone.0032561.g008
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mobile phase. Recombinant near full-length Hck was purified in
its downregulated conformation (Hck-YEEI) from Sf-9 insect cells
as described in detail elsewhere [44,53].
Nef-SH3 domain binding assay
GST-tagged Hck SH3 domain fusion proteins (wild-type and
W93A mutant) as well as GST alone were expressed in E. coli
BL21 Rosetta cells and immobilized on glutathione-agarose beads
according to our published protocol [61]. For Nef-SH3 binding
assays, each recombinant purified Nef protein (1 mg) was
incubated with an equimolar amount of immobilized GST or
the GST-SH3 fusion proteins in 500 ml of lysis buffer (50 mM
Tris-HCl, pH 7.4, 50 mM NaCl, 10 mM Mg2Cl, 1 mM EDTA,
1% Triton X-100) supplemented with protease inhibitors at 4uC
for 2 h. Binding reactions were then washed by resuspending the
beads 4 times in 1 ml RIPA buffer (50 mM Tris-HCl, pH 7.4,
150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, 1%
sodium deoxycholate) supplemented with protease inhibitors.
Associated Nef proteins were eluted in SDS-PAGE sample buffer
at 95uC for 10 min, separated by SDS-PAGE, and visualized by
immunoblotting with antibodies against the N-terminal His tag.
In vitro kinase assay
Nef-mediated activation of Hck tyrosine kinase activity was
assayed using the Z9-Lyte method with the Tyr2 peptide substrate
(Life Technologies). The principle of this FRET-based assay is
described in detail elsewhere [44,53]. Briefly, reactions (10 ml)
were conducted in 384-well plates. Recombinant Hck (25 ng) was
incubated with a 10-fold molar excess of each recombinant Nef
protein in the absence or presence of DFP-4A, DFP-4-AP, or
DFP-4AB (10 mM) [53] in kinase assay buffer (50 mM Hepes,
pH 7.5, 10 mMMgCl2, and 1 mM EGTA, 0.01% Brij-35) for 1 h
at room temperature. For experiments with Hck in the absence of
Nef, higher input kinase was used (75 ng) to achieve equivalent
levels of substrate phosphorylation to that observed in the presence
of Nef. Development reagent was then added to the reaction for an
additional 60 min at room temperature, followed by the stop
reagent. Fluorescence was assessed at an excitation wavelength of
400 nm; coumarin fluorescence and the fluorescein FRET signal
were monitored at 445 and 520 nm, respectively. Reactions run in
the absence of ATP served as the 0% phosphorylation control,
whereas stoichiometrically phosphorylated Tyr2 peptide was used
as the 100% phosphorylation control. Raw fluorescence values
were corrected for background, and reaction endpoints calculated
as emission ratios of coumarin fluorescence divided by the
fluorescein FRET signal. These ratios were then normalized to
the ratio obtained with the 100% phosphorylation control peptide.
Figure 9. Inhibition of HIV-1 Nef chimeras by 4-amino DFP
analogs. U87MG-CD4+/CXCR4+ cells (upper panel) and CEM-T4 cells
(lower panel) were infected with wild-type HIV-1 NL4-3, a Nef-defective
mutant (DNef), or the indicated Nef chimeras as described in the
legends to Figures 7 and 8. DFP-4A, DFP-4AP, or DFP-4AB were added
to the cultures to a final concentration of 3 mM, and viral replication was
determined by p24 ELISA 5 days (U87MG) or 10 days (CEM-T4) later.
Data are expressed as the mean percent of HIV-1 replication observed
in control cultures incubated with the carrier solvent (0.1% DMSO) 6
S.D. (n = 6).
doi:10.1371/journal.pone.0032561.g009
Figure 10. Inhibition of HIV-1 Nef chimera-mediated activation of SFKs by 4-amino DFP analogs. CEM-T4 cells were infected with wild-
type HIV-1 NL4-3 (WT), a Nef-defective mutant (DNef), or the indicated Nef chimeras in the absence or presence of 3 mM DFP-4A, DFP-4AP, DFP-4AB,
or the carrier solvent (DMSO) alone as a control (Con). SFK proteins were immunoprecipitated from infected cell lysates followed by immunoblotting
with a phosphospecific antibody against the activation loop phosphotyrosine residue common to all SFKs (pY418). Control blots were performed on
cell lysates for HIV-1 Gag proteins (p55, p40, and p24), Nef, as well as actin as a loading control. Results from uninfected cells are shown in the far right
lane (No virus). This experiment was repeated twice with comparable results.
doi:10.1371/journal.pone.0032561.g010
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Each condition was assayed in quadruplicate, and results are
presented as the mean 6 S.D.
Yeast assay for SFK activation
The yeast-based assay for analysis of SFK activation by Nef and
other viral proteins is described in detail elsewhere [44,52,64].
Briefly, Saccharomyces cerevisiae strain YPH 499 (Stratagene) was co-
transformed with pESC-Ura (or pYC2/CT-Ura) and pESC-Trp
plasmids containing the genes of interest via electroporation (Bio-
Rad GenePulser II). Transformed colonies were selected on
synthetic drop-out medium lacking uracil and tryptophan with
glucose as sole carbon source for 3 d at 30uC. Colonies were
cultured in galactose-containing medium lacking uracil and
tryptophan for 18 h at 30uC to induce gene expression. Cell
densities were normalized to an OD600 of 0.2 in water and lysed
with 0.1 N NaOH for 5 min at room temperature. Aliquots of
each lysate were separated via SDS-PAGE, transferred to
polyvinylidene difluoride (PVDF) membranes, and probed for
protein phosphotyrosine content by immunoblotting with anti-
phosphotyrosine antibodies. Replicate blots were probed for
expression of each SFK, Nef and actin as a loading control.
HIV-1 Nef chimera construction and viral replication
assays
To generate the HIV-1 Nef chimeras, unique Cla I restriction
sites flanking the Nef ORF were introduced into pUC18 carrying
the complete HIV-1 NL4-3 proviral DNA sequence (pUC18-NL4-
3) [53,58]. The coding sequences for the primary Nef genes as well
as Nef-SF2 were PCR-amplified with Cla I linkers and used to
replace the NL4-3 Nef sequence in pUC18-NL4-3. Control and
chimeric viruses were generated by transfection of 293T cells,
followed by amplification of the viral supernatants in the T cell
line, MT2. For HIV-1 replication assays, U87MG-CD4+/
CXCR4+ and CEM-T4 cells were incubated overnight in the
absence or presence of the DFP analogs in a final concentration of
0.1% DMSO as carrier solvent. U87MG-CD4+/CXCR4+ cells
were then infected with 200 pg p24/ml of each chimeric virus and
incubated for 5 d while CEM-T4 cells were infected with 62.5 pg
p24/ml of each chimeric virus for 10 d in 96-well plates. HIV-1
levels in the culture supernatants were then determined by p24
ELISA as described [53].
Activation of endogenous SFKs by HIV-1 Nef chimeras
CEM-T4 cells (16105 per T25 flask) were infected with 50 pg
p24 equivalents/ml of wild-type HIV-1 NL4-3, a Nef-defective
mutant (DNef), or the indicated Nef chimeras in a final culture
volume of 10 ml in the absence or presence of 3 mM DFP-4A,
DFP-4AP, DFP-4AB, or the carrier solvent (DMSO) alone as a
control (Con). The infected cells were lysed eight days later in
RIPA buffer and SFK proteins were immunoprecipitated with a
pan-specific antibody and protein-G sepharose beads as described
elsewhere [50,65]. SFK activation was assessed by immunoblot-
ting each immunoprecipitate with a phosphospecific antibody
against the activation loop phosphotyrosine residue common to all
Src family members (pY418; [61]). Control blots were performed
on cell lysates for HIV-1 Gag proteins (p55, p40, and p24), Nef, as
well as actin as a loading control.
Supporting Information
Figure S1 Expression of Nef alone, or together with the
SFK regulator Csk, has no effect on tyrosine phosphor-
ylation of yeast proteins. Control experiments investigated
whether Nef alone (or co-expression of Nef with the SFK
regulator, Csk) had any effect on tyrosine phosphorylation of
yeast proteins. Yeast cultures expressing each primary Nef allele as
well as Nef-SF2 and Nef-ELI were grown in defined medium with
galactose as sole carbon source to induce gene expression. Yeast
protein-tyrosine phosphorylation was evaluated by immunoblot-
ting of yeast cell lysates. None of the Nef proteins induced tyrosine
phosphorylation in the absence of a co-expressed SFK. Co-
expression of Nef-SF2 with Hck is included as a positive control
(left panels). Co-expression of Nef with Csk, the negative regulator
of SFKs, also did not induce yeast protein-tyrosine phosphoryla-
tion (right panels). In contrast, expression of c-Src (in the absence
of Csk) led to strong tyrosine phosphorylation of yeast proteins.
These results indicate that expression of Nef alone or Nef with Csk
does not induce tyrosine phosphorylation of yeast proteins,
consistent with the lack of endogenous SFK orthologs in yeast.
(TIFF)
Figure S2 Primary HIV-1 Nef proteins induce modest
activation of c-Src in yeast. Unlike the other SFKs used in the
yeast studies, modification of the c-Src tail with a YEEI tail did not
result in effective downregulation in the absence of Csk. Therefore
we decided to downregulate wild-type c-Src by co-expression of
Csk as described previously. Yeast cultures were co-transformed
with c-Src, Csk, and Nef expression plasmids, and protein
expression was induced in galactose medium as described under
Materials and Methods. Protein-tyrosine phosphorylation was
then evaluated by anti-phosphotyrosine immunoblotting. Expres-
sion of c-Src alone induced strong phosphorylation of yeast
proteins that was downregulated in the presence of Csk (Src+Csk).
Co-expression of Nef-SF2 overcame Csk-mediated c-Src inhibi-
tion, while Nef-ELI failed to activate c-Src. All of the primary Nef
proteins also activated Csk-downregulated c-Src kinase, albeit to a
lesser extent compared to Nef-SF2.
(TIFF)
Figure S3 Co-expression of c-Src with primary Nef
proteins induces growth arrest in yeast. To look for
additional evidence of Nef-mediated c-Src activation, we also
monitored yeast cell growth. Our previous work has shown that
ectopic expression of active SFKs induces growth arrest in yeast,
providing another measure of Nef-SFK interaction in this system.
For these experiments, aliquots of the transformed yeast cultures
shown were spotted over a series of dilutions on galactose-agar
plates, and the yeast patches appear as dark circles in the resulting
scanned images of the plates. Expression of c-Src alone induced
growth suppression compared to control cultures, while expression
of c-Src with Csk reversed this effect. Consistent with our previous
work, expression of Nef-SF2 overcame the inhibition of c-Src by
Csk, leading to growth suppression, while the non-interacting
allele Nef-ELI failed to do so. Co-expression of primary Nef
proteins with c-Src also induced growth suppression in the
presence of Csk, with the exceptions of Nef-A2, Nef-F2 and Nef-
H. These data provide additional evidence that primary Nef
proteins from almost all major HIV-1 clades activate c-Src. To
control for culture plating density, replicate dilutions of each
culture were also spotted on glucose-agar plates. Because glucose
represses protein expression from the GAL promoter, c-Src, Csk,
and Nef are not expressed and all cultures grow to the same extent.
(TIFF)
Figure S4 Primary HIV-1 Nef proteins do not activate
Lck, Fyn or Fgr in yeast. Here we examined whether primary
Nef proteins can activate other SFKs expressed in HIV-1 target
cells using the yeast assay. Primary Nef proteins were co-expressed
with the down-regulated (YEEI) forms of Lck, Fyn and Fgr,
followed by anti-phosphotyrosine immunoblotting of yeast cell
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lysates. Co-expression with Nef had no effect on Lck, Fyn or Fgr
kinase activity despite strong expression of the Nef proteins and
each SFK. As a positive control, we co-expressed Lck-YEEI with
the herpesvirus Tip protein, which binds to Lck and induces strong
kinase activation. Fyn and Fgr were also expressed as their wild-
type forms; in the absence of Csk, these SFKs induced strong yeast
tyrosine phosphorylation.
(TIFF)
Figure S5 Src-family kinase expression in CEM-T4
lymphoblasts. CEM-T4 cells were lysed in RIPA buffer (see
main text) and SFK protein expression was assessed by
immunoblotting with antibodies specific for the individual Src
family members shown. Lysates were also blotted with actin
antibodies as a loading control.
(TIFF)
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